LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 2 | M02 | 72 | hr | 1476 | 2035 | 3694 | 0.5509 | 0.2518 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 3 | M02 | 72 | hr | 1476 | 1877 | 3694 | 0.5081 | 0.1805 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 1 | O08 | 72 | hr | 1476 | 2839 | 3694 | 0.7685 | 0.6144 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 2 | O08 | 72 | hr | 1476 | 2562 | 3694 | 0.6936 | 0.4895 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 3 | O08 | 72 | hr | 1476 | 2658 | 3694 | 0.7195 | 0.5328 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 1 | J20 | 72 | hr | 1476 | 1516 | 3694 | 0.4104 | 0.0177 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 2 | J20 | 72 | hr | 1476 | 1884 | 3694 | 0.5100 | 0.1837 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 3 | J20 | 72 | hr | 1476 | 1754 | 3694 | 0.4748 | 0.1251 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 1476 | 1640 | 3694 | 0.4440 | 0.0736 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 1476 | 1475 | 3694 | 0.3993 | -0.0008 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 1476 | 1445 | 3694 | 0.3912 | -0.0143 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 1 | P14 | 72 | hr | 1476 | 3180 | 3694 | 0.8608 | 0.7682 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 2 | P14 | 72 | hr | 1476 | 3087 | 3694 | 0.8357 | 0.7262 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 3 | P14 | 72 | hr | 1476 | 3210 | 3694 | 0.8690 | 0.7817 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 1 | H02 | 72 | hr | 1476 | 1108 | 3694 | 0.2999 | -0.1663 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 2 | H02 | 72 | hr | 1476 | 967 | 3694 | 0.2618 | -0.2299 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 3 | H02 | 72 | hr | 1476 | 1018 | 3694 | 0.2756 | -0.2069 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 1 | L20 | 72 | hr | 1476 | 1379 | 3694 | 0.3733 | -0.0441 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 2 | L20 | 72 | hr | 1476 | 1351 | 3694 | 0.3657 | -0.0567 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 3 | L20 | 72 | hr | 1476 | 1486 | 3694 | 0.4023 | 0.0042 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 1 | H08 | 72 | hr | 1476 | 1284 | 3694 | 0.3476 | -0.0869 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 2 | H08 | 72 | hr | 1476 | 1324 | 3694 | 0.3584 | -0.0689 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 3 | H08 | 72 | hr | 1476 | 1293 | 3694 | 0.3500 | -0.0829 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 1 | G08 | 72 | hr | 1476 | 807 | 3694 | 0.2185 | -0.3020 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 2 | G08 | 72 | hr | 1476 | 881 | 3694 | 0.2385 | -0.2687 |